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Background: Sitagliptin is a highly selective dipeptidyl peptide-4 (DPP-4) inhibitor that increases blood levels of active gluca-
gon-like peptide (GLP)-1 and glucose-dependent insulinotrophic polypeptide (GIP), resulting in increased insulin secretion. 
While studies conducted in other countries have indicated the efficacy and safety of using sitagliptin to treat type 2 diabetes mel-
litus (T2DM), its predictors of effects to sitagliptin are not well understood. Therefore, we evaluated the predictive clinical param-
eters for the therapeutic benefits of sitagliptin when added to an ongoing metformin or sulfonylurea therapy in Korean T2DM 
subjects.
Methods: We obtained data from 251 Korean T2DM subjects who had recently started taking sitagliptin as add-on therapy. Ex-
clusion criteria included any insulin use. Changes in HbA1c (ΔHbA1c) and fasting plasma glucose (ΔFPG) were assessed by com-
paring baseline levels prior to sitagliptin administration to levels 12 and 24 weeks after treatment. Responders were defined as 
subjects who experienced decrease from baseline of >10% in ΔHbA1c or >20% in ΔFPG levels at 24 weeks.
Results: We classified 81% of the subjects (204 out of 251) as responders. The responder group had a lower mean body mass in-
dex (23.70±2.40 vs. 26.00±2.26, P≤0.01) and were younger (58.83±11.57 years vs. 62.87±12.09 years, P=0.03) than the non-re-
sponder group.
Conclusion: In Korean T2DM subjects, sitagliptin responders had lower body mass index and were younger compared to non-
responders.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a complex metabolic dis-
order caused by insufficient insulin secretion and insulin resis-
tance. Recently, the prevalences of T2DM and other metabolic 
abnormalities have increased in Korea due to their westernized 
lifestyle and nutritional status and together have become seri-
ous economic and social problems [1]. 
 In the last 10 years, several studies have shown that strict 
glycemic control is a most important factor in the prevention 
of macrovascular and microvascular complications [2-6]. So 
T2DM treatments focus on lifestyle changes, reducing hyper-
glycemia, and improving insulin sensitivity. Management in-
cludes measures such as weight loss and oral medications that 
improve insulin sensitivity and lower blood glucose by decreas-
ing insulin resistance. Since T2DM has progressively changing 
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characteristics, the identification of a uniform treatment plan 
for all patients is difficult. Moreover recent reports on the 
pathogenesis of T2DM in Korea suggest that impaired insulin 
secretion, especially selective beta cell loss, is more prominent 
than insulin resistance, even in the stage of impaired glucose 
[7]. The reasons for the above are not entirely clear, but differ-
ences in body fat distribution, insulin resistance, lipid profile 
and prevalence of hypertension may contribute. Thus, these 
racial or ethnic differences rise from not only genetic predis-
position but also environmental factors. Therefore individual 
treatment regimens need to be customized for each T2DM pa-
tients [8]. 
 Recently developed dipeptidyl peptide-4 (DPP-4) inhibitors 
prevent the degradation of glucagon-like peptide (GLP)-1, an 
important incretin in the body. GLP-1 increases the secretion 
of insulin and decreases the secretion of glucagon, thereby re-
ducing blood sugar. Since GLP-1 improves glucose tolerance 
[9,10], over 20 DPP-4 inhibitors are in development worldwide 
with sitagliptin and vildagliptin commonly used in Korea. 
DPP-4 inhibitor is clinically beneficial because its adverse ef-
fects are minimal by comparison other orally administered 
hypoglycemic agents. For example, it can safely be used by el-
derly individuals who are at increased risk of hypoglycemia, 
and weight gain and other gastrointestinal side effect are un-
common. Moreover in preclinical studies, DPP-4 inhibitor in-
creased the number of pancreatic beta cells and improved the 
function of beta cells and improved function [11].
 In the present study, we investigated the effectiveness of si-
taglipin as add-on therapy for subjects with T2DM who had 
inadequetly controlled blood sugar level with conventional 
oral hypoglycemic agents such as metformin and sulfonylurea. 
Treatment responses were examined and the factors affecting 
the overall effectiveness of sitagliptin use were analyzed.
METHODS
Subjects
The medical records of subjects with T2DM who visited the 
out-patient department or were admitted to Endocrinology 
and Metabolism Division at Yonsei University Gangnam Sev-
erance Hospital between January 2009 and January 2010 were 
reviewed. Subjects were enrolled if hemoglobin A1c (HbA1c)> 
7.5% before taking sitagliptin as add-on therapy. Exclusion 
criteria included any insulin use and dose change of anti-dia-
betic medication in study period.
Study design
A total of 251 subjects were administered an additional 100 
mg of sitagliptin together with metformin or metformin+ 
sulfonylurea. Fasting plasma glucose (FPG) and HbA1c levels 
were measured in these subjects before and 12 and 24 weeks 
after administration of sitagliptin. FPG levels were determined 
using a 747 automatic analyzer (Hitachi, Tokyo, Japan) and a 
standard glucose oxidase method. HbA1c levels were measured 
using high performance liquid chromatography.
 After 24 weeks, in order to assess the characteristics that af-
fect response to sitagliptin treatment, we defined responders 
as patients who achieved FPG reduction of >20% or HbA1c 
reduction of >10% from baseline. The factors affecting the re-
sponse of sitagliptin treatment were evaluated. The clinical 
characteristics between the response group and the non-re-
sponse group included the duration of T2DM, body mass in-
dex (BMI), plasma lipid concentrations, and insulin resistance 
levels. 
 BMI was calculated using the formula: weight (kg)/height 
(m2). Total cholesterol, high density lipoprotein cholesterol 
(HDL-C), and low density lipoprotein cholesterol (LDL-C) 
levels were measured by an enzymatic method using a 7,150 
autoanalyzer (Hitachi), and insulin and c-peptide were deter-
mined by radioimmunoassay. The homeostasis model assess-
ment of insulin resistance (HOMA-IR) was calculated using 
FPG and plasma insulin concentrations: fasting insulin (μU/
mL)×FPG (mmol/L)/22.5. beta cell function was also calcu-
lated using fasting insulin levels and the HOMA-β method: 
20×fasting insulin (μU/mL)/(FPG [mmol/L]-3.5).
Statistical analysis
All statistical analysis were performed with SPSS for Windows, 
version 17.0k (SPSS Inc., Chicago, IL, USA) and descriptive 
data were expressed as mean±standard deviation or as num-
ber. Continuous variables were compared between response 
group and the non-response group were analyzed using t-tests. 
More than three group analysis was performed using analysis 
of covariance (ANOVA), and logistic regression analysis was 
used to examine the relationships between the variable. P val-
ues of less than 0.05 were considered statistically significant.
RESULTS
Baseline clinical characteristics of subjects
Out of a total of 251 type 2 diabetic patients, 137 were men, and 
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114 were women. The mean age was 59.59±11.75 years. At 
baseline the mean value of HbA1c was 8.45±0.96%, FPG was 
161.93±37.55 mg/dL, post prandial 2 hour blood glucose 
(PP2) was 254.21±66.66 mg/dL. Insulin level was 8.70±11.85 
µIU/mL and C-peptide was 2.36±1.80 ng/mL. The average 
BMI was 24.14±2.54 kg/m2. Of the 251 subjects, 220 used si-
tagliptin together with metformin. Thirty-one patients re-
ceived sitagliptin together with sulfonylurea and metformin 
for T2DM treatment (Table 1).
Effect of sitagliptin in plasma glucose and HbA1c
After 12 weeks of additional sitagliptin administration, HbA1c 
was 7.49±0.94%, FPG was 138.08±32.62 mmol/L, and PP2 
was 196.27±64.59 mmol/L. After 24 weeks, HbA1c decreased 
to 7.25±0.97%, FPG decreased to 136.25±32.02 mmol/L, and 
PP2 decreased to 190.89±58.53 mmol/L (Fig. 1).
Predictive clinical characteristics of sitagliptin response 
group
Patients who achieved FPG reduction of >20% or HbA1c re-
duction of >10% after 24 weeks of sitagliptin administration 
were classified in the sitagliptin response group. Among 251 
subjects of treatment group, 204 (81%) were classified as re-
sponders. Biochemical and clinical factors that affected the si-
tagliptin response were evaluated between the response group 
and the non-response group. HbA1c reduced from 9.04±5.17% 
to 7.57±4.07% (ΔHbA1c=1.47±1.10%) in the response group. 
The response group was younger than the non-response group 
(58.83±11.57 vs. 62.87±12.09, P=0.03) and the BMI of re-
sponse group was also lower (23.70±2.40 vs. 26.00±2.26, 
P≤0.01). The duration of diabetes was shorter in the response 
group than the non-response group (6.80±6.14 vs. 10.42±9.23, 
P=0.14) and HOMA-β was also lower (34.10±42.84 vs. 54.35±
Table 1. Baseline characteristics of study subjects treated with 
sitagliptin
Characteristic Sitagliptin 
Sex, M:F 137:114
Age, yr 59.6±11.8 
DM duration, yr 7.7±6.5 
M:M+S 220:31 
SBP 123.1±12.4 
DBP 76.9±9.3 
BMI, kg/m2 24.1±2.5 
FPG, mg/dL 161.9±37.6
PP2, mg/dL 254.2±66.7
HbA1c, % 8.5±1.0
C-peptide, ng/mL 2.4±1.8
Fasting insulin, µIU/mL 8.7±11.9 
BUN, mg/dL 16.0±4.9
Creatinine, mg/dL 1.0±0.2
AST, IU/L 26.0±17.5
ALT, IU/L 27.5±20.3
TC, mg/dL 167.8±35.9
HDL-C, mg/dL 46.7±10.6 
LDL-C, mg/dL 93.2±32.8 
Triglyceride, mg/dL 148.0±77.5
Data are presented as number or mean±standard deviation.
DM, diabetes mellitus; M, metformin; S, sulfonylurea; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; BMI, body mass index; 
FPG, fasting plasma glucose; PP2, post prandial 2 hour blood glu-
cose; AST, aspartate amino transferase; ALT, amino alanine transfer-
ase; TC, total cholesterol; HDL-C, high density lipoprotein cholester-
ol; LDL-C, low density lipoprotein cholesterol.
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Fig. 1. Changes in HbA1c and FPG with sitagliptin treatment. 
The black bar indicates the response group and gray bar indi-
cates the non-response group. Bars represent mean+standard 
deviation. aP<0.05.
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94.98, P=0.08) but there was no statistically significant (Table 
2). After the t-test age, duration of diabetes, BMI, and HOMA-β 
were treated as independent variables, and regression analysis 
showed that there was no significant relationship between 
them, excluding BMI (P<0.05) which was discovered to be a 
dependent variable (Table 3). There was no significant differ-
ence between metformin+sitagliptin group and metformin+s
ulfonylurea+sitagliptin group. 
 In order to observe the response to sitagliptin treatment 
based on age, multigroup analyses were obtained. The ∆HbA1c 
in the subjects under 50 (n=40) was 1.44±1.04%, in the sub-
jects between 51 and 65 (n=104) was 1.32±1.31%, and in the 
subjects over 65 (n=70) was 1.00±0.90%. ∆HbA1c level 
showed a tendency to decrease based on age (Fig. 2A), but this 
trend was not statistically significant. The results of an analysis 
of the effect of sitagliptin based on duration of T2DM showed 
greater effectiveness in subjects treated lower than 5 years 
(n=69) with a ∆HbA1c of 1.33±1.12% compared subjects 
with longer duration of T2DM (n=56, 1.25±1.36%). However, 
this difference was not statistically significant (Fig. 2B). When 
the effects of sitagliptin were analyzed based on BMI, the 
∆HbA1c in the BMI ≤25 kg/m2 group (n=152) was 1.41±
1.07%, the 25 kg/m2 <BMI ≤30 kg/m2 group (n=30) was 0.77
±1.23%, the BMI >30 kg/m2 group (n=27) was 0.90±1.34%. 
Subjects with lower BMI were greater response in sitagliptin 
treatment (P=0.04) (Fig. 2C). The ∆HbA1c based on HOMA-β 
was 1.32±1.12% when HOMA-β≤22.3 (n=72), 1.27±1.05% 
when 22.3<HOMA-β≤48.2 (n=34), and 0.99±0.67% when 
HOMA-β>48.2 (n=25) (P=0.042). The sitagliptin response 
was higher in subjects with beta cell secretory dysfunction 
(Fig. 2D). 
DISCUSSION
In this study, we analyzed 251 subjects who were administered 
additional sitagliptin because of poor glycemic control with 
previous oral hypoglycemic agents. And the factors affecting 
the response of sitagliptin treatment in Korean T2DM were 
evaluated. The HbA1c lowering effect of sitagliptin was 1.55± 
1.01%, and in non-obese subjects and subjects with decreased 
insulin secretion the response to sitagliptin was very promis-
ing. Asian patients are less likely to be obese than Western pa-
tients. It is suggested that Koreans with reduced pancreatic in-
sulin secretion would be more effective in the sitagliptin treat-
ment. Insulin secretion is relatively preserved during the ini-
tial stages of type 2 diabetes. However, as the duration of dia-
betes longer, insulin deficiency progresses as a result of beta 
cell dysfunction. 
 In the other studies, it is reported that strict blood glucose 
control can delay the progression of microvascular and mac-
rovascular complications [6]. However, in a multicenter study 
of Korean hospitals, out of 5,652 T2DM patients who main-
tained a glycemic control target of HbA1c <7.0% were 36.7%, 
that considered to have unsatisfactory levels of glycemic con-
trol [12]. In addition, according to UK Prospective Diabetes 
Study (UKPDS) data, out of 826 patients who were newly di-
agnosed with T2DM and were being treated with sulfonylurea 
Table 2. Characteristics of responders and non-responders to 
sitagliptin (n=251)
Characteristic Responder (n=204)
Non-respond-
er (n=47) P value
Sex, M:F 115:89 22:25 0.237
Age, yr 58.8±11.6 62.9±12.1 0.034
DM duration, yr 6.8±6.1 10.4±9.2 0.146
BMI, kg/m2 23.7±2.4 26.0±2.3 <0.001
C-peptide, ng/mL 2.3±1.7 2.5±2.1 0.755
Fasting insulin, µIU/mL 8.6±11.9 9.0±11.8 0.887
FPG, mg/dL 165.8±37.7 145.1±31.8 0.001
HbA1c, % 9.0±5.2 8.0±0.5 <0.001
ΔHbA1c, % 1.5±1.1 0.1±0.5 0.001
HOMA-β 34.1±42.8 54.4±95.0 0.082
HOMA-IR 3.7±5.7 3.1±3.5 0.605
Data are presented as number or mean±standard deviation.
DM, diabetes mellitus; BMI, body mass index; FPG, fasting plasma 
glucose; HOMA-β, homeostasis model assessment of β–cell function; 
HOMA-IR, homeostasis model assessment of insulin resistance.
Table 3. Logistic regression analysis for predictive parameters 
of clinical efficacy of sitagliptin as dependent variables and its 
components as independent variables
OR 95% CI P value
 Age, yr 1.05 0.68 to 1.42 0.670
DM duration, yr 0.099 0.90 to 1.09 0.841
BMI, kg/m2 1.65 1.10 to 2.47 0.016
HOMA-β 0.91 0.76 to 1.08 0.278
Adjusted for age, sex, BMI, HbA1c. 
OR, odds ratio; CI, confidence interval; DM, diabetes mellitus; BMI, 
body mass index; HOMA-β, homeostasis model assessment of β–cell 
function.
163
Efficacy of sitagliptin in diabetes mellitus
Diabetes Metab J 2011;35:159-165http://e-dmj.org
53% had poor glycemic control and required insulin injections 
after six years. Based on these results active insulin treatment 
is recognized as a necessity in type 2 diabetic patients and the 
research interest in insulin injection time intervals and in in-
sulin types is increasing. However, it has been reported in sev-
eral studies that continuous high doses of insulin are associat-
ed with increased risk of cancer [13-15]. 
 The goal for T2DM treatment is to administer sufficient 
amounts of insulin in vivo to effectively control plasma glucose 
without causing severe hypoglycemia. Therefore drugs with 
different mechanisms of action are needed. For the last 5 years 
novel drugs have been developed and are currently being used 
in many countries including Korea. These drugs include incre-
tin mimetics like GLP-1 analogues and DPP-4 inhibitors. Sita-
gliptin is an orally active, potent and selective DPP-4 inhibitor 
in development for the treatment of T2DM. Sitagliptin acts 
through increasing active incretin hormone concentrations. 
Following ingestion of a meal, incretins, including GLP-1 and 
glucose-dependent insulinotrophic polypeptide (GIP) attenu-
ate the post-meal rise in glucose concentration and reduce 
fasting glucose concentrations. Both GLP-1 and GIP are rap-
idly inactivated by the enzyme DPP-4. In patients with type 2 
diabetes, treatment with single doses of sitagliptin provided 
sustained 24 hour inhibition of DPP-4 enzyme activity and in-
creased active GLP-1 and GIP concentrations.
 A 0.6% reduction of HbA1c was observed in an 18-week 
study of 100 mg sitagliptin monotherapy vs. placebo [16]. In a 
24 week study of 100 mg and 200 mg sitagliptin monotherapy 
vs. placebo involving 741 type 2 diabetic patients the <8% 
HbA1c level group had 0.57% reduction in HbA1c, and the 
over 9% group had 1.52% reduction [10]. Drug effectiveness 
was much higher in the elevated HbA1c group. Although many 
combination therapies involving sitagliptin have been designed, 
HbA1c decreased 0.6% when sitagliptin was administered 
compared with a placebo in a 24 week study involving 702 pa-
tients who were not controlled with metformin [17]. In a 24-
week study enrolled 353 patients who were not controlled with 
pioglitazone, HbA1c decreased 0.7% when compared with a 
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placebo [18].  This amount may exceed the moderate hypogly-
cemic effects of existing drugs, but its predictors of effects to 
sitagliptin are not well understood. Therefore, we evaluated 
the predictive clinical parameters for the therapeutic benefits 
of sitagliptin when added to an ongoing metformin or sulfo-
nylurea therapy in Korean T2DM subjects.
 In this study 251 subjects who received 100 mg sitagliptin in 
combination with sulfonylurea and metformin for 24 weeks 
exhibited a mean decrease in HbA1c of 1.23±1.15%. The re-
sponders were higher baseline HbA1c level compared with 
non-responders. So a more effect was expected in patients with 
relatively high baseline HbA1c levels in sitagliptin treatment. 
Based on HbA1c and FPG levels before and after treatment 
and in comparisons of the clinical characteristics and biochem-
ical parameters of the response group and the non-response 
group, the response group’s BMI and HOMA-ß levels were 
significantly lower. Thus greater effects of sitagliptin are ex-
pected in Korean diabetic patients who have quantitative pan-
creatic deficiencies [7]. 
 Sitagliptin blocks the degradation of endogenous and exog-
enous GLP-1 and increases insulin secretion and action. In 
addition, it inhibits the secretion of glucagon, thereby decreas-
ing plasma glucagon values, which in turn reduces blood glu-
cose and improves glucose tolerance. In this study, more than 
81% of patients were found to have improved glucose toler-
ance. These results suggest that sitagliptin treatment exerts 
significant effects in patients who have decreasing secretory 
capacity in pancreatic beta cells and that DPP-4 inhibitors may 
also improve beta cell function [19]. According to a previous 
animal study, sitagliptin improved beta cell function and in-
creased insulin secretion [20]. The administration of DPP-4 
inhibitor decreases blood glucose, decreases glucagon, and 
improves beta cell function in humans [21].
 This study has several limitations. First, since this was a ret-
rospective study the accuracy of our results may have been 
compromised. Second, although only Korean subjects were 
used in this study and there was no control group. Third, diet 
and exercise were not monitored while the participants of this 
study were receiving treatment. However despite these limita-
tions, in Korean T2DM subjects, sitagliptin responders had 
lower BMI and were younger compared to non-responders. 
Further prospective randomized controlled studies are needed 
to obtain more detailed information.
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